$GILD (Gilead Sciences Inc.)

$GILD {{ '2016-02-03T10:41:44+0000' | timeago}} • Announcement

$GILD's BoD approved a $12Bil repurchase program to start upon completion of the existing $15Bil repurchase program authorized in Jan. 2015. As of Dec. 31, 2015, about $8Bil remained in the Jan. 2015 program. $GILD intends to use $5Bil of the remaining Jan. 2015 program in the next 3 months under an accelerated share repurchase program.

$GILD {{ '2018-01-18T17:34:32+0000' | timeago}} • Announcement

Kite, a $GILD company, has entered into a clinical trial collaboration with Pfizer, Inc. to evaluate the safety and efficacy of the combination of Yescarta and Pfizer's utomilumab, in patients with refractory large B-cell lymphoma. A multi-center Phase 1/2 study sponsored by Kite is expected to begin in 2018.

$GILD {{ '2017-12-15T12:38:30+0000' | timeago}} • Announcement

$GILD announced that Executive Chairman John Martin will transition from his current role of Executive Chairman to Chairman of the Board of Directors effective March 9, 2018.

$GILD {{ '2017-12-12T14:09:39+0000' | timeago}} • Announcement

Kite, a $GILD company, announced updated results from the ongoing Phase 1/2 ZUMA-3 study of KTE-C19, a CD19 CAR T cell therapy, which is investigational for treatment of adults with relapsed or refractory acute lymphoblastic leukemia (ALL). 71% of ALL patients who received a single infusion of KTE-C19 achieved complete tumor remission.

$GILD {{ '2017-12-11T13:19:50+0000' | timeago}} • Announcement

Kite, a $GILD company reported that 58% of  patients with advanced blood cancer, who underwent a one-time treatment of its Yescarta therapy, showed complete remission after a median of 15 months. The company added that 42% of the patients continued to respond to therapy, after the duration of this period

$GILD {{ '2017-12-08T12:53:28+0000' | timeago}} • Announcement

$GILD and Kite agreed to acquire Cell Design Labs, Inc. $GILD will acquire all outstanding shares of Cell Design Labs, which includes approx. 12.2% of shares held by Kite, for up to approx. $567MM. The agreement includes an initial upfront payment of about $175MM and milestone payments of up to $322MM. The acquisition is expected to close shortly.

$GILD {{ '2017-12-04T15:30:42+0000' | timeago}} • Announcement

$GILD launched the Gilead COMPASS Initiative, a 10-year, $100MM commitment to support organizations working to address the HIV/AIDS epidemic in Southern US. $GILD will partner with the Emory University Rollins School of Public Health, the University of Houston Graduate College of Social Work and the Southern AIDS Coalition for this initiative.

$GILD {{ '2017-10-27T18:39:37+0000' | timeago}} • Webcast

$GILD expects Yescarta will become the standard-of-care for diffuse large B-cell lymphoma after oral therapy. The company has done the clinical trials in diffuse large B-cell lymphoma in around 15 centers mainly focusing in the US. $GILD is currently expanding to most centers in the US and also in Europe.

$GILD {{ '2017-10-27T18:39:19+0000' | timeago}} • Webcast

In 3Q17, $GILD’s HIV and HBV franchise delivered revenues of $2.7Bil in the US. TAF-based regimens now account for 56% of the company’s total HIV prescription volume, up from 39% as it entered 2017. In Europe, total HIV and HBV revenues were $716MM in 3Q17, down 2% YoY and down 2% sequentially.

$GILD {{ '2017-10-27T18:39:01+0000' | timeago}} • Webcast

During 3Q17, $GILD’s product sales in the US were $4.5Bil, down 10% YoY and 9% sequentially. HCV product sales were $1.4Bil, down 31% YoY and 26% sequentially, primarily driven by lower patient starts and increased competition. Non-HCV product sales were $3.1Bil, up 4% YoY, and 2% sequentially, primarily due to higher demand for TAF-based regimens.

$GILD {{ '2017-10-26T23:24:11+0000' | timeago}} • Announcement

$GILD declared a cash dividend of $0.52 per share of common stock for 4Q17, payable on December 28, 2017, to stockholders of record on December 15, 2017.

$GILD {{ '2017-10-26T23:20:36+0000' | timeago}} • Announcement

For FY17, $GILD expects net product sales to be $24.5-25.5Bil. Non-HCV product sales are expected to be $16-16.5Bil while HCV product sales are expected to be $8.5-9Bil. Adjusted product GM is expected to be 86-87%.

$GILD {{ '2017-10-26T23:20:20+0000' | timeago}} • Announcement

$GILD reported net income of $2.7Bil or $2.06 per share in 3Q17 compared to $3.3Bil or $2.49 per share in 3Q16. Adjusted net income was $3Bil or $2.27 per share in 3Q17. Total revenues were $6.5Bil in 3Q17 compared to $7.5Bil in 3Q16.

$GILD {{ '2017-10-26T21:11:34+0000' | timeago}} • Infographic

$GILD Gilead Sciences Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$GILD {{ '2017-10-24T15:21:32+0000' | timeago}} • Announcement

$GILD announced positive results from a Phase 2 trial evaluating GS-0976 in the treatment of nonalcoholic steatohepatitis (NASH). After 12 weeks, a higher dose of GS-0976 was associated with significant reductions in liver fat buildup and a noninvasive marker of fibrosis compared to placebo. NASH is a disease that can significantly harm the liver.

$GILD {{ '2017-10-19T16:10:20+0000' | timeago}} • Announcement

$GILD received approval from the US FDA for Yescarta, a new gene therapy developed by Kite Pharma for the treatment of adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments. Yescarta is a CAR-T therapy, which reprograms the body’s own immune cells to recognize and attack malignant cells.

$GILD {{ '2017-10-17T16:06:03+0000' | timeago}} • Announcement

$GILD announced the promotion of Alessandro Riva, MD, to EVP, Oncology Therapeutics, with responsibility for the company’s hematology and oncology programs, including cell therapy research and development.

$GILD {{ '2017-10-04T14:22:07+0000' | timeago}} • Announcement

$GILD announced results from a Phase 3 study evaluating the efficacy of a fixed-dose combination of bictegravir (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (FTC/TAF), a dual-NRTI backbone in HIV-1-infected patients. The study found BIC/FTC/TAF to be superior to other regimens.

$GILD {{ '2017-10-04T13:59:54+0000' | timeago}} • Announcement

$GILD has also expanded its licensing agreements with Sun Pharmaceutical Industries Limited, Strides Shasun Limited, Mylan Laboratories Limited and SeQuent Scientific Limited to include BIC, and products incorporating the compound, for distribution in 116 developing countries.

$GILD {{ '2017-10-04T13:59:38+0000' | timeago}} • Announcement

$GILD announced a new licensing agreement with the Medicines Patent Pool (MPP) to expand access to bictegravir (BIC) upon regulatory approval in the US. BIC is used to treat HIV-1 infection. MPP can sub-license rights to BIC to companies in India, China and South Africa to manufacture therapies containing BIC for distribution in 116 countries.

$GILD {{ '2017-09-27T21:15:40+0000' | timeago}} • Announcement

$GILD announced that Kevin Young CBE, COO, plans to retire, effective early 2018. Mr. Young will remain with $GILD through 1Q18 and in an advisory capacity thereafter.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
SGMO (Sangamo Biosciences Inc.)
Thursday, November 9 2017 - 10:00pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
BTX (BioTime, Inc.)
Thursday, November 9 2017 - 9:30pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
RGEN (Repligen Corporation)
Thursday, November 9 2017 - 1:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
INSM (Insmed Incorporated)
Thursday, November 2 2017 - 12:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
TECH (Bio-Techne Corp.)
Tuesday, October 31 2017 - 1:00pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, October 26 2017 - 8:30pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
ALKS (Alkermes plc)
Thursday, October 26 2017 - 12:30pm
AMGN (Amgen Inc)
Wednesday, October 25 2017 - 9:00pm

AlphaGraphics you may like